INSTITUTE OF MEDICINE WORKSHOP
REVIEWING EVIDENCE TO IDENTIFY HIGHLY EFFECTIVE CLINICAL SERVICES
JANUARY 25, 2007
PANEL 4—STAKEHOLDERS FORUM
Moderator: Robert Galvin (General Electric)
Panelists: Kathy Buto (J&J), Vivian Coates (ECRI), Art Small (Genentech), James Weinstein (Dept. of Orthopedics, Dartmouth-Hitchcock Medical Center)
The objective of this panel discussion is to learn key stakeholders’ views on how highly effective clinical services are identified. Johnson & Johnson is one of the world’s largest manufacturers of medical devices, drugs, and equipment. ECRI, an AHRQ-designated Evidence-based Practice Center, is a highly respected source of evidence-based assessments of the clinical effectiveness of medical procedures, devices, and drugs. Genentech is one of the world’s leading biotech companies. Dartmouth-Hitchcock’s department of orthopedics is the primary site of a 5-year, $14 million trial comparing surgical to nonsurgical treatments for certain back problems.
This IOM Committee has been charged with recommending an approach to identifying highly effective clinical services across the spectrum of care—from prevention, diagnosis, treatment, and rehabilitation, to end-of-life care and palliation. In light of this charge and from the perspective of your organization, please answer the following:
How do you think that priorities should be set for services that need evidence development or synthesis?
What is your organization’s current role in the development, use, and analysis of evidence on the clinical effectiveness of health care services (including drugs, devices, procedures, and other methods used to promote health or rehabilitation)?
Several groups and individuals—perhaps most recently Gail Wilensky in a Health Affairs piece1—have proposed the establishment of a sizable entity to effect a quantum leap in the national capacity to assess the comparative effectiveness of health care services. How